May 20, 2025 05:20AM Mainz Biomed (MYNZ) Announces Pricing of $4M Follow-On Offering of Ordinary Shares and Warrants

May 16, 2025 08:02AM Mainz Biomed (MYNZ) Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Apr 28, 2025 08:01AM Mainz Biomed (MYNZ) Provides Q1 Corporate Update and Path to FDA Premarket Approval

Mar 27, 2025 09:01AM Mainz Biomed (MYNZ) Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mar 13, 2025 08:01AM Mainz Biomed (MYNZ) and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Feb 11, 2025 08:01AM Mainz Biomed (MYNZ) and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening

Jan 27, 2025 08:01AM Mainz Biomed (MYNZ) Regains Nasdaq Compliance

Jan 21, 2025 08:01AM Mainz Biomed (MYNZ) Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Dec 19, 2024 08:03AM Mainz Biomed (MYNZ) Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Nov 29, 2024 08:48AM Mainz Biomed (MYNZ) Announces 1-for-40 Stock Split

Nov 5, 2024 08:04AM Mainz Biomed (MYNZ) files for 30.77M share and warrant offering

Oct 21, 2024 08:02AM Mainz Biomed (MYNZ) Reports Mid-Year 2024 Financial Results, Provides Corporate Update

Oct 1, 2024 08:02AM Mainz Biomed (MYNZ) CEO Issues Update

Sep 4, 2024 07:10AM Mainz Biomed (MYNZ) Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Jul 25, 2024 08:03AM Mainz Biomed (MYNZ) Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Jul 9, 2024 05:39AM Mainz Biomed (MYNZ) Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Jul 2, 2024 08:01AM Mainz Biomed (MYNZ) Issues Half Year 2024 Corporate Update